Additionally, TAMs can decrease ICI efficacy by 1) directly blocking CD8+ T cells’ anti-tumor functions and tumor infiltration ability (25, 27, 33), 2) expressing alternate immune checkpoints (i.e., VISTA) or 3) sequestering ICI antibodies (25, 27, 34–36). The gene discussed is CD8A; the disease is neoplasm.